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Abstract
Several in vitro and in vivo studies have examined the positive and negative effects of retinoids
(vitamin A analogs) in premalignant and malignant lesions. Retinoids have been used as
chemopreventive and anticancer agents because of their pleiotropic regulator function in cell
differentiation, growth, proliferation and apoptosis through interaction with two types of nuclear
receptors: retinoic acid receptors and retinoid X receptors. Recent investigations have gradually
elucidated the function of retinoids and their signaling pathways and may explain the failure of
earlier chemopreventive studies.
In this review we have compiled basic and recent knowledge regarding the role of retinoid
receptors in lung carcinogenesis. Sensitive and appropriate biological tools are necessary for
screening the risk population and monitoring the efficacy of chemoprevention. Investigation of
retinoid receptors is important and may contribute to the establishment of new strategies in
chemoprevention for high-risk patients and in the treatment of lung cancer.
Background
Despite antismoking efforts and advances in therapy, lung
cancer remains the leading cause of cancer-related death
worldwide [1].
Multi-step carcinogenesis has been described as "a gradual
accumulation of genetic and epigenetic aberrations result-
ing in the deregulation of cellular homeostasis" [2]. There
is a similarity between bronchial lesions found in carcin-
ogen-treated animals (squamous metaplasia) and the his-
tological changes affecting the bronchial epithelia of
humans or animals deficient in vitamin A. Restoration to
a normal histological state occurs after vitamin A reple-
tion, which in experimental models has also been shown
to confer protection against pro-carcinogens.
The term retinoid (first coined by Sporn in 1976) gener-
ally refers to naturally occurring and synthetic vitamin A
(retinol) metabolites and analogs [3].
Several studies have shown that vitamin A/retinoids are
physiological regulators of embryonic development,
vision, reproduction, bone formation, haematopoesis,
differentiation, proliferation and apoptosis. Pharmaco-
logically, they have been recognized as modulators of cell
growth, differentiation and apoptosis. Furthermore they
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organs (e.g. oral cancer, skin, bladder, lung, prostate and
breast cancers) in experimental animals [4]. Clinically,
retinoids reverse premalignant human epithelial lesions
and prevent lung, liver and breast cancer and second pri-
mary tumors in the head and neck [5].
It is now generally thought that the effects of retinoids are
mainly mediated by the nuclear retinoid receptors, which
are members of the steroid and thyroid hormone receptor
superfamily [6,7]. Two families of retinoic receptors have
been identified, namely RARs and RXRs with three sub-
types for each (α; β, γ) and several isoforms arising from
promoter usage and alternate splicing. The retinoid recep-
tors are ligand-activated, DNA binding trans-acting, tran-
scription-modulating proteins. The three RAR types have
a strong affinity for all-trans and 9-cis isomers of retinoic
acid. The three RXR types, on the other hand, have dem-
onstrated an especially strong specificity for only the 9-cis
isomers. Studies have shown that RXR/RAR heterodimers
are responsible for transducing the retinoid signal in vivo
[8]. These heterodimers bind to retinoic acid response ele-
ments found in the promoter region of retinoic acid-
inducible target genes thereby activating transcription
[8,9]. Without ligand RAR-RXR, heterodimers bind to co-
repressors, which play an active role in repressing the tran-
scription of targeted genes. The recruitment of histone
deacetylases (HDACs) brings about transcriptional repres-
sion by preventing the opening of chromatin, which is
linked to deacetylation of nucleosomes [10]. Several of
the co-activators and co-repressors are shared by multiple
signaling pathways, e.g. CBP (cAMP response element
binding protein) has been implicated in AP-1 (activator
protein 1) and p53 signaling. Meanwhile STAT signaling,
Sin3 and HDAC-1 seem to have a role in what Ayer, et. al.
call "Mad-Max signaling" [4].
Dawson lists a series of nuclear receptors such as thyroid
hormone receptors, vitamin D3 receptors (VDRs), peroxi-
some proliferator activated receptors (PPARs), and several
orphan receptors in which RXR is important as a "het-
erodimeric partner" [11].
The RARs and RXRs exhibit the conserved module struc-
ture of nuclear receptors and their amino acid sequence
can be divided into six regions (A-F) based on homology
among themselves and with other members of the nuclear
superfamily.
The central region C consists of 66 amino acids and has
two zinc-binding motifs very much like the core of the
DNA binding domain (DBD) which enables cognate
response elements to be recognized specifically. Both this
central C region and the functionally complex E region are
highly conserved between RARs and RXRs. Region E gains
its complexity from the ligand binding domain (LBD), the
ligand-dependent transcriptional activation function AF-
2, and a dimerization surface contained within it. The
name AF-1 has been given to a second transcriptional acti-
vation function found in both the amino-terminal A/B
regions.
In humans, the genes encoding RAR α, β and γ are respec-
tively located on chromosomes 17q21.1, 3p24 and
12q13. Those for RXR α, β and γ lie on chromosomes
9q34.3, 6p21.3, and 1q22. The physiological importance
of the multiple isoforms of RARs is not known precisely,
but these isoforms may explain why RARs have pleio-
tropic biological effects.
There are two major isoforms for RARα (α1 and α2) and
for RAR γ (γ1 and γ2), and four major isoforms for RARβ
(β1–β4) and the recently described RARβ1' [12], whose
absence seems to be responsible for retinoid resistance in
lung carcinognesis. RAR isoforms can be classified as
those which are transcribed from either the P1 (class I:
RAR α1, β1, and β3, γ1) or P2 (class II: RARα2, β2 and β4,
γ2) promoter. All class II isoform P2 promoters contain an
RA response element and are RA-inducible to varying
degrees [13].
Similarly, several isoforms differing from one another in
their amino-terminal region have been identified for
RXRα (α1, α2), RXRβ (β1 and β2), and RXRγ (γ1, γ2) [14].
Epigenetic and genetic changes
Respiratory epithelium carcinogenesis is a multifactorial
process which includes inherited and acquired genetic
changes, chromosomal rearrangements, epigenetic phe-
nomena and chemical carcinogenesis.
Vitamin A deficiency has been associated with bronchial
metaplasia and increased lung cancer development. Many
other factors contribute to dysfunction of retinoids and
their cognate receptors [2].
The first cytogenetic reports connecting chromosome 3 to
lung cancers were those of Whang-Peng et al. [15,16], who
reported that 100% of small cell lung cancer (SCLC) cases
examined showed specific 3p deletions by Giemsa band-
ing. These changes were observed in 12/12 cell lines and
three fresh tumors after a two-day culture period. The
minimal region of common deletion was 3p14-p25. A
number of studies have since been undertaken that
obtained similar results that were extended to non small
cell lung cancer (NSCLC).
Houle et al. mapped the RARβ2 at 3p24 and demon-
strated that expression was decreased or even suppressed
in lung cancer cell lines, suggesting that its re-expressionPage 2 of 7
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mRNA expression has been described in both primary
NSCLCs and bronchial biopsy specimens from heavy
smokers [18,19]. Furthermore, in addition to lung cancer
[18,20], decreased RARβ2 mRNA expression has been
demonstrated in a variety of solid tumors including head
and neck [21]and breast carcinomas [22]. Xu et al. [18]
also reported that all RARs and RXRs were expressed in at
least 89% of control normal bronchial tissue specimens
from patients without a primary lung cancer and that in
distant normal bronchus specimens from patients with
NSCLC RARα, RXRα and γ were expressed in more than
95% of the tumor-free specimens. In contrast, RARβ, RARγ
and RXRβ expression was decreased, detected in only 76%
of NSCLC specimens. Picard et. al similarly showed
diminished or absent RARβ protein expression in ~50% of
resected NSCLCs [23]. Furthermore, these authors
observed normal or elevated RARα and RXRα expression
in NSCLCs. The expression of RARβ, RARγ, and RXRβ was
found to be decreased, however, in many tumors, while
LOH at 3p24 occurred at a high frequency. This phenom-
enon was also seen in non-neoplastic lesions. The authors
concluded that altered retinoid receptor expression might
be involved in lung carcinogenesis. Martinet et al.
extended the above study investigating RARs and RXRs
alteration in lung cancer precursor lesions. They per-
formed allelotyping for microsatellites located near the
RAR/RXR gene loci and immunohistochemistry was addi-
tionally carried out to evaluate P53 and RARβ expression.
Microsatellite changes occurred frequently in all samples,
but without specificity for any group. RARβ marker losses
were found in all examined groups, with a concomitant
RARβ protein expression [24].
Aberrant methylation of the promoter regions of genes is
a major mechanism of gene silencing in tumors [25]. Vir-
many et al. [26] identified hypermethylation as the under-
lying mechanism for this frequent loss of RARβ
expression. Twenty-one of 49 (43%) primary resected
NSCLC samples showed RARβ hypermethylation. In addi-
tion, it was demonstrated that RARβ hypermethylation
was also important in the pathogenesis of SCLCs, with
62% of SCLCs methylated for RARβ. In the same study, it
was also demonstrated that treatment of lung cancer cell
lines with the demethylation agent 5-aza-2'-deoxycytidine
(5-AZA-CdR) can restore RARβ expression. Moreover, a
phase I-II trial in patients with stage IV NSCLC suggests
that 5-AZA-CdR may have some clinical activity against
metastatic NSCLC [27]. The loss of RARβ mRNA expres-
sion has been observed in many lung cancer cell lines also
suggesting that to function as a tumor suppressor gene,
RARβ expression is contingent on the intracellular con-
centration of retinoids [28]. The effects of retinol (vitamin
A) depend on its intracellular metabolism including its
transport by specialized proteins such as Cellular Retinol
Binding Proteins (CRBP) and on its binding as retinoic
acid to specific nuclear receptors: the Retinoic Acid Recep-
tors (RARs) and the Retinoid X Receptors (RXRs) [7]. The
CRBP I and II transport retinol in the cell and serve as
chaperon proteins to prevent unscheduled retinol catabo-
lism. It is the first building block in retinoic acid synthesis.
Retinoid signaling
The mechanisms through which retinoids suppress car-
cinogenesis, although complex, are gradually being eluci-
dated. Their complexity results from the large number of
genes involved in tumor cell differentiation and prolifera-
tion that include retinoic acid response elements in their
promoters. Retinoids also inhibit tumorigenesis and
tumor growth through their ability to induce either apop-
tosis (programmed cell death) or terminal differentiation.
Interestingly, it has been established that the apoptotic
process triggered by Retinoid Related Molecules is inde-
pendent of p53 activation and proceeds through a novel
pathway in which the mitochondrion seems to play a piv-
otal role [29].
As Karamouzis et al. stated in a recent publication [2], a
'switch on/off' model determines the relationship
between retinoid receptors and other signaling pathways
during bronchial carcinogenesis. According to this model,
RXR selective compounds specifically inhibit AP-1 (activa-
tor protein 1) activity resulting in inhibited cell prolifera-
tion in normal respiratory epithelium, RARβ and RXRα
AP-1-dependent interaction with other nuclear receptors,
such as PPARγ with contribution cofactors (CBP/
p300cAMP response element binding protein), ensures
cyclin D1 mediated cell cycle inhibition, hence favoring
apoptosis or differentiation. Down-regulation of the
RARβ mechanism (as detailed above) combined with CBP
and AP-1 up-regulation triggers tumor progression and
proliferation. Concurrently the inability of RXRα to form
heterodimers with PPARγ enables an AP1/CBP-dependent
up-regulation of Cox2, resulting in the inhibition of apop-
tosis. This crucial role of RXRs may explain the observa-
tion of Brabender et. al as well. They observed suppressed
mRNA expression of all subtypes of RXRs in curatively
resected NSCLC that is followed by statistically worse
overall survival [30].
In addition, retinoids play a central role in tumor stroma
production and thus in the control of tumor progression
and invasion through their ability to regulate the expres-
sion of matrix metalloproteinases, transforming growth
factor-β, and cell cycle regulator proteins, such as cyclin
dependent kinase I, such as p16, or p21 [31,32].
Up to now, the use of retinoids in clinical trials has been
limited because of their pharmacologic effects and side
effects. Furthermore a majority of human or experimentalPage 3 of 7
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mechanism of retinoic acid resistance has not been totally
elucidated. The absence of the newly recognized RARβ1'
(alternatively spliced from RARβ1 isoform) could be one
reason for retinoid resistance in lung carcinogenesis [12].
In that study RARβ1' expression was repressed in RA-
resistant BEAS-2B-R1 cells in lung cancer, compared with
adjacent normal lung tissues. In H358 lung cancer cells
that were transiently transfected with RARβ1', RA treat-
ment was able to restore target gene expression. In order
to better understand the mechanism of RARβ1' repression
more studies are needed, and the authors note that
"potential reexpression in lung cancer may be important
to future approaches to lung cancer chemoprevention"
[33].
Chemoprevention
Chemoprevention has been defined as: the application of
natural or synthetic molecules to prevent, inhibit or
reverse the carcinogenic machinery [34].
For the respiratory tract there are two major classes of
agents which appear to prevent damage induced by
inhaled carcinogens: retinoids and antioxidants. (In addi-
tion to those mentioned above, new classes of chemopre-
ventive agents are under investigation, such as EGFR
inhibitors, farnesyl transferase inhibitors, Cyclooxygen-
ase-2 inhibitors etc., but presently we are focused on retin-
oids and synthetic Retinoid Related Molecules (RRMs).
Clinical trials have shown how complex the chemopre-
vention approach is. Nevertheless, large primary preven-
tion trials in volunteers (physicians and nurses in the
Physicians Health Study) and in high-risk populations
(smokers, ex smokers and asbestos workers in the CARET
and ATBC studies, and in the more recent EUROSCAN
trial) using either beta-carotene, or the combination of
beta-carotene and retinyl palmitate and the combination
of beta-carotene and alpha-tocopherol have documented
a higher incidence of lung cancer among smoking partici-
pants who received beta-carotene [35,36]. Interestingly a
negative effect of beta-carotene supplementation has also
been observed in experimental animals exposed to ciga-
rette smoke [37]. In the EUROSCAN study, where retinyl
palmitate and/or N-acetylcisteine supplementation were
used, no beneficial effects on the incidence of second pri-
mary cancer and survival were observed. There was one
exception for retinal given to workers exposed to asbesto-
sis, which seemed almost protective against mesotheli-
oma development [38]. One possible explanation for the
failure and harm seen in the chemoprevention trials could
be the procarcinogenic effect of the toxic oxidative caro-
tene metabolites. The oxidative metabolites induce cyto-
chrome P450 enzymes, lowering the serum levels of
retinoid acid and down regulating RXR and RARβ. Nico-
tine by itself inhibits RARβ expression via methylation.
Further randomized, controlled chemoprevention trials
designed to test retinoids, β-carotenes or α-tocopherol
defined their target population based on smoking history,
preneoplastic changes of the bronchial epithelium, or
cancer history [39] (Table 1).
In a recent study Lam S. et al. observed that retinol was not
effective in the up-regulation of RARβ in lesions with
bronchial dysplasia among individuals who continued to
smoke [40].
In addition Khurie FR. et al. reported worse prognosis in
stage I. lung cancer, which indicated maintenance of
RARβ expression and overexpression of RARβ correlated
with increased expression of cyclooxygenase-2, an enzyme
that contributes to progressive carcinogenesis and is a
marker of poor prognosis [41,42].
The gene promoter hypermethylation is a leading cause of
gene silencing. The loss of RARβ expression due to hyper-
methylation is of interest as are bronchial premalignant
Table 1: Lung cancer chemoprevention trials on retinoic acid analogs
Study Drug Number of patients End point Result Reference
ATBC β-Carotene 29,133 Lung cancer Negative/harmful [57]
α-Tocoferol
CARET β-Carotene 18,314 Lung cancer Negative/harmful [58]
Retinol
EUROSCAN Retinyl-palmitate 2,592 Second primary tumor Negative [38]
N-Acetycystein
Physician's Health Study β-Carotene 22,071 Lung cancer Negative [59]
Pastorino et al. Retinyl-palmitate 307 Second primary tumor Positive [35]
Lam et al. ADT 112 Bronchial dysplasia Positive [40]
Kurie et al. Fenretinide 82 Metaplasia Negative [60]
Lippman et al. 13cRA 1,304 Second primary tumor Negative [61]
ATBC, α-Tocoferol, β-Carotene Cancer Prevention Study; CARET, Carotene and Retinol Efficacy Test; ADT, anethole dithioethione (5-[p-
methoxyphenyl]-1,2-dithiole-3-thione; 13cRA, 13 cis retinoic acidPage 4 of 7
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show that hypermethylation of RARβ2 genes has a differ-
ent effect on the development of second primary lung can-
cers (SPLCs) in NSCLCs depending on smoking status. In
current smokers, SPLCs developed more frequently when
RARβ was unmethylated than when it was hypermethyl-
ated. In the case of former smokers it was the opposite.
SPLCs were more prevalent in patients with hypermethyl-
ated RARβ. Thus, in active smokers, silencing RARβ
expression by hypermethylation has a protective effect
against the development of SPLCs, whereas in former
smokers RARβ expression (unmethylated) appears to be
protective. The authors suggested that in current smokers,
the continuous high oxygen tension and free radicals
induce apoptosis and offer protection from the SPLCs.
This apoptosis may be inhibited by retinoic acid if RARβ
is expressed on a normal level [43]. These findings explain
in part the previous observation that RARβ expression is
associated with poor prognosis among patients who are
active smokers [44].
Now available are stronger synthetic retinoids that select
for an RAR and RXR type without exposing patients to the
kind of retinoid toxicity that had previously been
observed [45,46]. Aerosolized early on site, these retin-
oids have been able to reverse the RR deficiency in stabi-
lizing RAR/RXR expression for increased ligand binding to
restore normal cellular differentiation [47]. The authors,
collaborating with a French research group, conceived and
designed an appropriate RR assay in order to measure effi-
ciently the normal bronchial mucosa level of each Retin-
oid Receptor's mRNA by real time quantitative relative RT-
PCR. This method could be useful for screening the RR's
status in the damaged bronchial epithelia of the high-risk
patient and for monitoring the efficacy of the different
Retinoids used as chemopreventive agents [48].
Summary
There is a large body of literature on clinical and preclini-
cal studies using natural retinoids and related compounds
for the prevention and the treatment of cancer [49]. The
field of lung cancer chemoprevention has been controver-
sial until now. However, there has also been disappoint-
ment in extending the therapeutic use of bexarotene
(selective RXR agonist) to patients with NSCLC. Although
preclinical data and a phase II clinical trial suggested that
bexarotene added to platinum based chemotherapy may
improve overall survival [50], a subsequent Phase III clin-
ical trial did not bear this out [51,52]. One possible rea-
son is that solid tumors can acquire and develop intrinsic
resistance to retinoids during carcinogenesis. The effects
of receptor selective retinoids on NSCLC cell lines were
examined by Sun et al. According to their findings 8 of the
37 retinoids showed growth-inhibitory activity (IC50, <10
μM) against at least two of the eight NSCLC cell lines [53].
CD437, a retinoid with some selectivity toward RARγ, was
highly effective [54]. The RXR selective compounds did
show growth inhibitory effects when combined with the
RAR retinoids. These results indicated that human lung
cancer cell lines have a high degree of resistance to syn-
thetic retinoids [55]. Freemantle et al. have summarized
the potential mechanisms of Retinoic Acid resistance.
Increased P450 catabolism, drug export (P glycoprotein
mediated), sequestration of retinoids by CRABs or other
proteins, decreased expression of RARs through promoter
methylation, persistent histone deacethylation, RAR rear-
rangement or mutation in the RAR ligand binding
domain, and coactivator alteration or alterations down-
stream of target gene expression may lead to cellular retin-
oid resistance. This knowledge should aid in predicting
those most likely to benefit from retinoid therapy and in
developing strategies to optimize single agent or combi-
nation retinoid regimens to overcome resistance [56]. The
generation of retinoids and rexinoids with restricted selec-
tivity has opened new possibilities for cancer therapy and
chemoprevention. It is probable that demethylating and
chromatin remodeling agents currently under clinical
investigation could be combined with these new retinoids
for a better restoration of RR expression.
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